For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.

TitleEntry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
Publication TypeJournal Article
Year of Publication2007
AuthorsKetas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP
JournalVirology
Volume364
Issue2
Pagination431-40
Date Published2007 Aug 1
ISSN0042-6822
KeywordsAnimals, Anti-Infective Agents, Local, Drug Evaluation, Preclinical, Drug Interactions, Female, HIV Fusion Inhibitors, HIV Infections, HIV-1, Humans, Male, Piperazines, Pyrazoles, Pyridines, Receptors, CCR5, Receptors, CXCR4, Sexual Behavior, Valine, Virus Internalization
Abstract

Inhibitors of viral entry are under consideration as topical microbicides to prevent HIV-1 sexual transmission. Small molecules targeting HIV-1 gp120 (BMS-378806) or CCR5 (CMPD167), and a peptide fusion inhibitor (C52L), each blocks vaginal infection of macaques by a SHIV. A microbicide, however, must be active against multiple HIV-1 variants. We therefore tested BMS-C (a BMS-378806 derivative), CMPD167, C52L and the CXCR4 ligand AMD3465, alone and in combination, against 25 primary R5, 12 X4 and 7 R5X4 isolates from subtypes A-G. At high concentrations (0.1-1 microM), the replication of most R5 isolates in human donor lymphocytes was inhibited by >90%. At lower concentrations, double and triple combinations were more effective than individual inhibitors. Similar results were obtained with X4 viruses when AMD3465 was substituted for CMPD167. The R5X4 viruses were inhibited by combining AMD3465 with CMPD167, or by the coreceptor-independent compounds. Thus, combining entry inhibitors may improve microbicide effectiveness.

DOI10.1016/j.virol.2007.03.001
Alternate JournalVirology
PubMed ID17428517
Grant ListU19 AI65413 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587